Clinical Trials Logo

Hypercalcemia clinical trials

View clinical trials related to Hypercalcemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01725113 Terminated - Kidney Failure Clinical Trials

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

ECRIP
Start date: November 2012
Phase: Phase 4
Study type: Interventional

The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.

NCT ID: NCT00458796 Terminated - Breast Cancer Clinical Trials

Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Start date: March 2006
Phase: N/A
Study type: Interventional

RATIONALE: Zoledronic acid may help decrease the risk of broken bones, bone pain, and other symptoms caused by bone metastases. It may also help patients live more comfortably. PURPOSE: This randomized clinical trial is studying different schedules of zoledronic acid to compare how well they work in treating patients with breast cancer that has spread to the bone.

NCT ID: NCT00415584 Terminated - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

Start date: January 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Secondary hyperparathyroidism can persist following successful renal transplantation and can cause high blood calcium, kidney dysfunction or failure and excessive bone loss among other problems. If the condition does not resolve, surgery is frequently required to remove the parathyroid glands, with all the inherent risks of surgery. Cinacalcet, a medicine used to treat secondary hyperparathyroidism in patients with kidney disease, may be effective in treating this condition in the renal transplant recipient. We will study the effect of cinacalcet on calcium, bone and renal function in a 6 month treatment protocol.